CV
PD Dr. rer. nat. Cécile Gouttefangeas
Academic education
1988 - 1989: Diploma thesis at the INSERM Unit 93, University Paris VII, France. (head of Department: Prof. Dr. L. Degos)
1984 - 1988: Study in Biochemistry, University Paris XI, France
1984: Baccalaureat Mathématiques et Sciences de la Nature (Abitur), Académie de Versailles, France.
Scientific degrees
2023: apl professorship ("außerplanmäßige Professorin"), Eberhard Karls University, Tübingen
2016: Habilitation: Immunology, Eberhard Karls University, Tübingen (Title: Effector T cells against cancer). Supervisor: prof. Dr. Hans-Georg Rammensee.
1993: Doctorat (Dr. rer. nat./ Ph.D): INSERM Unit 93, University Paris VII, France (Title: Phenotypic and functional identifiaction of human T-lymphocyte subsets). Supervisor: Professor Dr. L. Degos/Dr. L. Boumsell.
Scientific career
2004 - present: Group leader at the Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany (Immune monitoring), Teaching activities at the University of Tübingen (since 2008), Delegate for ethics matters at the Department of Immunology (2005-2018), Delegate for the DKTK immune-monitoring strategy workgroup (start 2018)
2001 - present: Scientific associate at the Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany
1997 - 2001: Post-doctoral position at the Institute for Cell Biology, Department of Immunology (head Prof. H. G. Rammensee), Tübingen, Germany. (Tumor antigen-derived CD8+ T cell epitopes).
1994 - 1996: Post-doctoral position at the INSERM Unit 395 (head Prof. C. de Préval), Toulouse, France.
Honors/ Awards/ Memberships
Fellowships
Post-doctorate: Fellowship from the European Union (Marie Curie Program), Grants from the Association for Cancer Research (ARC) and the National League Against Cancer (LNCC).
Diploma and doctoral theses: Fellowships from the Ministry of Education and Ministry of Research, France.
Memberships
2015 - present: DGfI member.
2007 - present: Member of the Cancer Immunotherapy Consortium of the Cancer Research Institute (CIC-CRI).
2006 - present: Member of the Association for Cancer Immunotherapy (CIMT).
2005 - present: member of the steering committee, chair (2012-2013) and active participant of the CIMT Immunoguiding Program (CIP), a working group of the Association for Cancer Immunotherapy (CIMT). www.cimt.eu/workgroups/CIP.
Others
2016: Co-organization of the 1st EMBL/DFG Women in Science Network Conference “From Genes, Cells and the Immune System towards Therapies”, 19-20 Sept 2016, Heidelberg.
Reviewer for international peer review journals (Frontiers in Oncology, Cancer Immunology Immunotherapy, International Journal of Cancer, Journal of Immunotherapy of Cancer, Vaccine…) and external reviewer for grant applications (Research Fund Denmark, ANR France, FNRS Belgium)
2011: Medizindidaktische Qualifikation I, Kompetenzzentrum für Hochschuldidaktik in Medizin, Baden-Württemberg.
10 most relevant publications
Schöllhorn A, Maia, Kimmerle F, Born J, Rammensee HG, Dimitrov S*, Gouttefangeas C*. Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells* Contributed equally. Front Immunol 2023;13:1107366
Gouttefangeas C, Klein R, Maia A. The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer. Frontiers Immunol 2023;14:1212546 (review)
Löffler MW, Gori S, Izzo F, … Gouttefangeas C, …Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro, L. HepaVac-101: a novel therapeutic cancer vaccine for hepatocellular carcinoma. Clinical Cancer Res 2022;28:2555
Richardson JR, Schöllhorn A, Gouttefangeas C, Schuhmacher J. CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy. Cancers; 2021;13:596 (review)
Traenkle B, Kaiser PD, Pezzana S, Richardson J, …, Gouttefangeas C, Kneilling M, Pichler BJ, Sonanini, Rothbauer U. Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells. Front Immunol2021;12:799910
Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P, Røder MA, Brasso K, Gouttefangeas C. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J Immunother Cancer2020;8(2):e001157
Rammensee HG, Wiesmüller KH, Chandran AP, Zelba H, Rusch E, Gouttefangeas C, …Weide B, Schippert W, Stevanović S, Löffler MW. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. Journal for Immunother of Cancer 2019;7:307
Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran PA, Stenzl A, Rammensee HG, Gouttefangeas C. PD-1 and LAG-3 dominate checkpoint receptor-mediated T cell inhibition in renal cell carcinoma. Cancer Immunol Res 2019;11:1891-1899
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, …, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019;565:240-245
Dimitrov S*, Gouttefangeas C*, Besedovsky L, Jensen ATR, Chandran PA, Rusch E, Businger R, Schindler M, Lange T, Born J, Rammensee HG*. Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation. Proc Natl Acad Sci U S A 2018;115:E5536-E5545. *corresponding authors
Patents
- Co-inventor of international patents on HLA-peptides and T-cell epitopes derived of (WO/2009/138236, WO/2011/073215, WO2012079878), and adjuvants (WO2018211113)
Contact Information
Prof. (apl) Dr. rer. nat. Cécile Gouttefangeas
Group Leader
University of Tübingen
Institute for Immunology
